| 产品描述： | CYC-116 is a potent aurora A and aurora B inhibitor with Kis of 8 and 9 nM, respectively. |
| 靶点： |
Aurora A:8 nM (Ki);Aurora B:9.2 nM (Ki) |
| 体内研究： |
Oral administration of CYC-116 at dose levels of 75 and 100 mg/kg q.d. causes tumor growth delays of 2.3 and 5.8 days, which translates into specific growth delays of 0.32 and 0.81, respectively. The mean relative tumor volumes of mice receiving CYC-116 at both dose levels are less than those of vehicle-treated mice for the duration of the study period. At 100 mg/kg po q.d., the reduction in growth is statistically significant on days 6 and 9 |
| 参考文献： |
1. Wang S, et al. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010 Jun 10;53(11):4367-78. |
| 溶解性： |
DMSO : 15 mg/mL (40.71 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) |
| 保存条件： |
-20℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.714 ml |
13.57 ml |
27.14 ml |
| 5 mM |
0.543 ml |
2.714 ml |
5.428 ml |
| 10 mM |
0.271 ml |
1.357 ml |
2.714 ml |
| 50 mM |
0.054 ml |
0.271 ml |
0.543 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京